UnknownNot Applicable

The Effect of Dual Trigger (GnRH Agonist + hCG) for Final Maturation in Oocyte Donors With History of a Previous Cycle With Suboptimal Response to GnRH Agonist Only Trigger

Greece80 participantsStarted 2023-11-01

Plain-language summary

The goal of this clinical trial is to compare GnRH-agonist trigger with dual GnRH-agonist and HCG trigger in oocyte donors. The main questions it aims to answer are: * Maturation rate (Metaphase II/ Total number of COCs collected) * Fertilization rate * Embryo quality day 3 * Fragmentation rate embryo day 3 * Blastulation rate (Day5/6/7) * Quality of blastocyst (Gardner criteria) Participants will undergo controlled ovarian stimulation with a GnRH antagonist protocol Researchers will compare the effects of final maturation with GnRH-agonist trigger to a dual trigger (hCG and GnRH-a)

Who can participate

Age range20 Years – 30 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * BMI: 18 - 25 * AMH: 1-3ng/ml * AFC: 15 * Peak E2 in previous ovarian stimulation cycle: \< 4000 pg/ml * Ovarian response in first stimulation cycle: \< 20 follicles over 10mm in total, at time of triggering * Peak E2 in study cycle: \< 4000 pg/ml * Suboptimal response to trigger medication at first stimulation cycle * Male age \< 50 years old with normospermia Exclusion Criteria: * Oocyte donors which are at risk for development of ovarian hyperstimulation syndrome (OHSS)

What they're measuring

Oocyte maturation rate

Timeframe: 18 months prospective trial

Fertilization rate

Timeframe: 18 months prospective trial

Blastulation rate

Timeframe: 18 months prospective trial

Trial details

NCT IDNCT06142708

SponsorEmbryolab Fertility Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-04

View on ClinicalTrials.gov More Ovarian Stimulation trials